Could J&J's Darzalex success spur it to buy out partner Genmab? Maybe so, one analyst says

30th November 2017 Uncategorised 0

Wednesday, multiple myeloma medication Darzalex hit a development milestone, triggering a $20 million payment from Johnson & Johnson for Genmab. But the way one analyst sees it, the Big Pharma may eventually tire of shelling out payments and take matters into its own hands.

More: Could J&J's Darzalex success spur it to buy out partner Genmab? Maybe so, one analyst says
Source: fierce